

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/041,860

Filing Date January 7, 2002

First Named Inventor Corvalan et al.

Art Unit 1644

Examiner Name Phuong N. Huynh

Attorney Docket Number Cura 961

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard Exhibits A, B, and C
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
<b>Remarks</b>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	CuraGen Corporation		
Signature			
Printed name	Wendy L. Davis		
Date	May 2, 2005	Reg. No.	38, 427

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name


Lissette Cartagena-Perez

Date May 2, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

AF / 1644



Express Mail Label No.:  
Date of Deposit: May 2, 2005

Attorney Docket No. Cura 961

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Corvalan et al.  
SERIAL NUMBER: 10/041,860 EXAMINER: Phuong N Huynh  
FILING DATE: January 7, 2002 ART UNIT: 1644  
FOR: ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF.

Commissioner for Patents  
P.O. Box 1450  
Washington, D.C. 22313-1450

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116.

This paper is in response to the March 1, 2005 Final Office Action in connection with the above-referenced application. Please enter the following amendments and consider the remarks below. Included with this response are: Exhibit A, Ostendorf, T. et al "A Fully Human Monoclonal Antibody (CR002) Identifies PDGF-D as a Novel Mediator of Mesangioproliferative Glomerulonephritis", J Am Soc Nephrol 14:2237-2247, 2003; Exhibit B, Rabbitts, T. H. (1983). Biochem. Soc. Trans., 11, 119-126; and Exhibit C, Corbett et al (1997). J. Mol. Biol., 270, 587-597. The Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment of same to Deposit Account No. 502648, Reference No. Cura 961.

Amendments to the Claims are reflected in the listing of the claims which begins on page 2 of this paper.

Amendments to the Drawings begins on page 6 of this paper.

Remarks begin on page 7 of this paper.